Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. by Kahan, BC et al.
TRIALS
Kahan et al. Trials 2014, 15:456
http://www.trialsjournal.com/content/15/1/456RESEARCH Open AccessReducing bias in open-label trials where blinded
outcome assessment is not feasible: strategies from
two randomised trials
Brennan C Kahan1*, Suzie Cro2, Caroline J Doré3, Daniel J Bratton2, Sunita Rehal2, Nick A Maskell4, Najib Rahman5
and Vipul Jairath6Abstract
Background: Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not
always feasible. It is therefore important to find other means of reducing bias in these scenarios.
Methods: We describe two randomised trials where blinded outcome assessment was not possible, and discuss
the strategies used to reduce the possibility of bias.
Results: TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of
the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a
blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant
information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified
to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the
outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper
gastrointestinal tract confirmed by an internal examination).
TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage
procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many
clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up.
Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the
decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural
space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to
reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in
the patient’s care, while reducing the potential for bias.
Conclusions: When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or
method of assessment to reduce the risk of bias.
Trial registration: TRIGGER: ISRCTN85757829. Registered 26 July 2012.
TAPPS: ISRCTN47845793. Registered 28 May 2012.
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The main goal of a randomised controlled trial (RCT) is
to ensure that, apart from the intervention, there are no
systematic differences between treatment groups under
study, thereby ensuring an unbiased estimate of treatment
effect. However, randomisation alone does not preclude
the possibility of systematic differences. If patients, clini-
cians, or assessors are aware of treatment assignments,
this may influence reporting or measurement of the out-
come and introduce bias [1]. For example, enthusiasm for
a newer treatment could lead to better outcomes being
reported in this group of patients, regardless of any treat-
ment efficacy.
It is therefore recommended that trials be blinded (or
masked) as far as possible to limit bias [2,3]. However, in
some cases the nature of the treatments under investiga-
tion may not permit blinding. This can be an issue in trials
assessing surgical interventions, device trials, or other
non-pharmacologic interventions, which are more difficult
to blind than traditional drug trials [4]. Many such trials
are therefore open-label, where patients, clinicians, and
care providers are aware of treatment allocations.
For objective outcomes, such as all-cause mortality,
unblinded assessment is unlikely to bias the trial results
[5]. However, evidence suggests that treatment effect
estimates may be exaggerated for subjective outcomes
when outcome assessors are not blinded [6-13]. This bias
can often be prevented by ensuring outcome assessors are
blind to treatment allocation, for example by using inde-
pendent clinicians who are not otherwise involved in the
trial to assess patients, or using a blinded adjudication
committee to determine outcome [14]. However, blinded
outcome assessment may not always be feasible due to
the nature of the trial (for example, when all researchers
in a centre are aware of treatment allocation, or relevant
information cannot be sent to a blinded adjudication
committee).
Developing methods to reduce bias when blinding is
not possible has recently been identified as a research
priority following a Delphi process involving all UK
registered clinical trials units [15]. This article highlights
the strategies that were employed in the design and exe-
cution of two multi-centre UK trials to reduce potential
for bias where blinded outcome assessment was not
feasible, with the aim of providing guidance from ‘real-life’
examples to clinicians and researchers planning studies
with similar challenges.
Methods
Issues to consider for blinded outcome assessment
The goal of blinded outcome assessment is to ensure that
bias is not introduced due to knowledge of the patient’s
treatment group. However, blinded outcome assessment
alone is not sufficient to prevent bias; it is also necessaryto ensure that the information upon which the assessment
is based is not subject to bias.
For example, consider a trial where a blinded adjudica-
tion committee determines whether an adverse event has
occurred based on a description of the event prepared by
an unblinded researcher. Knowledge of the patient’s treat-
ment arm may influence how the event summary was pre-
pared by the researcher (for example, under or overstating
certain aspects), which could in turn affect the assessment
of the adjudication committee.
Therefore, prevention of outcome assessment bias re-
quires two components. The first is that those making
the assessment are blinded to which treatment arm the
patient is in. The second is that the information upon
which the assessment is made cannot have been influenced
by knowledge of the treatment assignment.When is blinded assessment not possible?
Two common methods of blinded outcome assessment
are to have a blinded clinician directly assess the patient
to determine the outcome, or to have a blinded adjudica-
tion committee assess the outcome based on information
provided about the patient. We discuss some scenarios
below where these methods of blinded assessment may be
difficult or impossible to achieve.Direct assessment by a blinded clinician
Blinded assessment may not be feasible in trials where all
clinicians or researchers in a centre are aware of treatment
assignment by necessity (for example, in a cluster rando-
mised trial where all patients in a centre receive the same
treatment). In some trials, it may be logistically impossible
to ensure a blinded clinician is always available to assess
the patient; this is a particular issue when the timings of
assessment occur randomly, for example if patients need
to be assessed when symptoms occur, rather than at fixed
time points.Blinded adjudication committee
The use of a blinded adjudication committee may be im-
practical when the relevant information is not available
to send to the committee, or when the information pro-
vided to the committee may have been influenced by
knowledge of the treatment allocation. For example, a
photo or a video may be required for the committee to
make an informed assessment; however, the technology
may not be routinely available for this. In other cases,
the committee may require a narrative of the event or
symptoms for their assessment. However, if it is only
feasible for an unblinded person to prepare this narra-
tive, this could introduce bias despite the use of a
blinded adjudication committee.
Kahan et al. Trials 2014, 15:456 Page 3 of 6
http://www.trialsjournal.com/content/15/1/456Outcomes that are not assessed
Some outcomes may be subject to bias due to lack of
blinding, but are not formally assessed (making it impos-
sible for a blinded adjudication committee to eliminate
bias). An example of this type of outcome is whether a
patient received ancillary interventions or supplemental
care (that is a co-intervention) during the follow-up
period [3]. This outcome is not assessed (as it either
occurred or did not), but could still be subject to bias if
the clinician who decides whether to perform the co-
intervention is aware of the treatment assignment.
Ethical approvals
TRIGGER was conducted according to the declaration of
Helsinki, and received ethical approval from the Scotland
A Research Ethics Committee (Reference 12/SS/0023)
and the NRES Committee South Central - Oxford C
(Reference 12/SC/0062). Consent was obtained for data
collection on all enrolled patients.
TAPPS was conducted according to the declaration of
Helsinki, and received ethical approval from the NRES
Committee North West - Preston (Reference 12/NW/
0467). All patients provided consent to take part in the
trial.
Results
Using two recent UK multi-centred trials as examples,
we highlight the methods that were used to reduce the
potential for bias where blinded outcome assessment
was not feasible.
TRIGGER
Trial overview
TRIGGER (Transfusion in Gastrointestinal Bleeding)
was a cluster randomised feasibility trial comparing two
different red blood cell transfusion policies (liberal versus
restrictive) in patients presenting to emergency depart-
ments in UK hospitals with acute upper gastrointestinal
bleeding (AUGIB) [16,17]. AUGIB is a common medical
emergency most commonly caused by peptic ulcer dis-
ease. Due to the perceived risk of contamination between
treatment policies in an individually randomised design,
as well as the inherent challenges of implementing a
transfusion policy for an emergency medical condition
throughout an entire hospital for the whole of the
patient journey, TRIGGER was designed as a cluster
randomised trial, meaning that all patients within a
given hospital received the same transfusion policy.
Due to the nature of the intervention (administering a
blood transfusion), and the fact that the intervention was
implemented hospital wide, it was necessary for all clini-
cians and study personnel in a centre to be aware of the
randomised transfusion policy. The primary clinical out-
come was further bleeding up to 28 days from presentation.Feasibility of blinded assessment
A direct assessment by a blinded clinician was not feasible
for TRIGGER, as all clinicians in a hospital were aware of
the allocated treatment and so would be unsuitable. Ask-
ing clinicians from another hospital to assess outcomes
would have been unrealistic, as further bleeding requires
assessment when it is suspected. As this could happen at
any time, it would be logistically impossible for a clinician
from another hospital to always be available to assess
patients.
Using a blinded adjudication committee to determine
the presence of further bleeding was also not feasible.
Whilst it is possible to take photos of the bleeding lesion
during an endoscopy (an internal examination using a
fibre optic camera), this facility is not always routinely
available, particularly when procedures are performed
‘out of hours’ in an emergency setting, which is likely to
occur frequently for a condition like AUGIB. Therefore,
the adjudication committee would need to base their deci-
sion on a composite of clinical parameters (for example,
clinical signs, symptoms, blood tests) which may be a poor
surrogate marker of further bleeding, or from a review of
case notes or descriptive information prepared by an
unblinded clinician, in which case the advantages of a
blinded assessor are lost.
Assessment method
Because blinded assessment is not feasible, further bleed-
ing was determined by an unblinded clinician. In order to
limit the potential for bias due to unblinded assessment,
the clinically accepted definition of further bleeding was
modified to ensure it was as objective as possible, thus
reducing the potential impact of unblinded assessment.
Further bleeding was defined as either ongoing bleeding
at the end of the first endoscopy, or bleeding that restarted
after initially stopping. Unlike in standard practice, where
further bleeding is often defined purely on the basis of
surrogate markers including a combination of patient
symptoms (for example, vomiting blood) and clinical pa-
rameters (for example, a sudden drop in haemoglobin
(Hb) count), assessment of bleeding in TRIGGER was via
inspection of the patient’s upper gastrointestinal tract to
determine whether there was an active bleed; this must
have been performed using endoscopy, surgery, or radi-
ology. The outcome assessment was therefore based sim-
ply on the presence of blood versus absence of blood,
which was unlikely to have been affected by whether the
assessor was aware of the treatment allocation.
TAPPS
Trial overview
TAPPS was a randomised trial assessing the manage-
ment of patients with malignant pleural effusions (fluid
in the chest cavity), which often leads to breathlessness
Kahan et al. Trials 2014, 15:456 Page 4 of 6
http://www.trialsjournal.com/content/15/1/456and chest pain. Patients were randomised to one of two
methods of fluid drainage and administration of talc
(which aims to stick the lung to the chest wall and pre-
vent further fluid formation): (a) talc slurry pleurodesis,
which involves inserting a chest drain into the pleural
space, and inserting talc slurry (a suspension of talc in
normal saline in a syringe) through the drain; or (b)
thoracoscopic talc poudrage, which involves inserting a
thoracoscope (small videoscope) into the pleural space,
and inserting talc using a dry spray technique.
The two interventions used different medical instru-
ments and different techniques of reaching the pleural
space, and so blinding of patients or study personnel
was impossible. The primary outcome was whether the
patient received a further procedure for pleural drainage
within 90 days of randomisation.
Choices of assessment method
Clinicians who were not directly involved in the care of
a specific patient were unaware of the treatment alloca-
tion, and could therefore be used as blinded assessors to
determine whether the patient should undergo further
intervention, making direct assessment by a blinded
assessor feasible. However, this option was not accept-
able practically, as a large proportion of clinicians may
feel it is unacceptable for treatment decisions for their
patients to be made without their input, and may there-
fore not be willing to take part in the trial, jeopardising
recruitment.
A blinded adjudication committee could assess whether
a patient should have undergone further pleural drainage,
rather than whether they did undergo a further procedure.
This could be based on a combination of clinical para-
meters (for example, results from a chest x-ray) and a
description of the patient’s symptoms prepared by a
blinded clinician. However, an adjudicated outcome of
whether the patient should have undergone further pleural
drainage could be regarded as a less pragmatic outcome,
and thus the treatment effect from such an outcome may
not reflect what is likely to occur in usual practice [18].
Additionally, this outcome could be problematic in sce-
narios where the patient is referred for further drainage
when the adjudication committee does not feel it is war-
ranted. This is because the further drainage effectively
prevents the patient from developing symptoms which
would lead the adjudication committee to recommend
further drainage is warranted at a future time point. This
is known as a competing-risk [19], and could potentially
lead to bias, or a reduction in power.
Final decision on assessment method
To limit bias, the decision to refer patients for further
drainage was made using a combination of clinical param-
eters, and blinded and unblinded assessment: If a chest x-ray showed that a third or more of the
patient’s pleural space was filled with fluid, then the
unblinded clinician in charge of patient care could
refer the patient for further drainage. There is no
need for a blinded assessment in this scenario as it is
clear that fluid recurrence has occurred, and further
intervention is indicated.
 If less than a third of the pleural space was filled
with fluid, then the unblinded clinician in charge of
patient care discussed whether further pleural
drainage was required (taking care not to unblind
them). If the two clinicians disagreed, they discussed
the case with the (blinded) chief investigator who
made the final decision.
This strategy (a) led to the outcome being based on
results from the patient’s chest x-ray when clearly indi-
cated; (b) allowed the unblinded clinician responsible
for the patient to be involved in their management; and
(c) attempted to mitigate any potential bias from the
unblinded clinician by introducing a second, blinded
assessor into the process.
Discussion
Many trial designs do not permit blinding, and are there-
fore designed as open-label, with patients, clinicians, and
other study investigators aware of treatment allocation.
Research has suggested that these trials should use blinded
outcome assessment to avoid bias in estimated treatment
effects [6-10]. Blinded outcome assessment is often
achieved by using an independent clinician who directly
examines the patient, or by an independent adjudication
committee.
However, in some scenarios both of these methods of
blinded assessment may be unfeasible. A direct blinded
assessment of the patient may be difficult in scenarios
where most or all of the staff in a centre are aware of
the patient’s treatment, or when assessments occur ran-
domly (for example, when the patient presents due to
symptoms). Likewise, the use of a blinded adjudication
committee may be complicated in situations where it is
difficult to compile information to send to the commit-
tee (for example, due to limitations in technology), or
when it is necessary for the information to be prepared
by unblinded personnel, which could bias results despite
the use of a blinded committee. Additionally, some out-
comes do not require assessment (for example, whether
the patient has received a co-intervention), but may none-
theless be biased by knowledge of the treatment arm.
When blinded outcome assessment is not feasible, it is
important to ensure that outcomes are as robust as
possible to the lack of blinding. We have demonstrated
with both the TAPPS and the TRIGGER trials that out-
come definitions or the methods of assessment can be
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highlighted as a trial methodology priority, yet there
are few examples in the literature to guide clinicians
planning trials.
This strategy is particularly important given the shift
away from surrogate outcome measures towards outcomes
that are directly relevant to patients. For example, previous
trials in patients with malignant pleural effusion have often
used the amount of fluid on a patient’s chest x-ray as a
surrogate for pleurodesis failure [20]. This can be easily
assessed by a blinded adjudicator, minimising the risk of
bias. However, this outcome is not relevant to patients, as a
small amount of fluid on a chest x-ray could still result in
severe symptoms, requiring further treatment, and vice
versa. Similarly, previous trials in patients with AUGIB
have often used a fall in the patient’s Hb level as a surro-
gate for further bleeding (along with other less objective
measures, as described earlier) [21]. Although a drop in the
Hb level will be objective (and thus unlikely to be subject
to bias), it may be a poor surrogate for actual bleeding
episodes. This is because there is sometimes a lag between
the development of bleeding and the Hb drop, so patients
can experience significant blood loss without a correspond-
ing drop in Hb.
The TAPPS and TRIGGER trials both used patient-
relevant outcome measures, which has the benefit of
measuring treatment effects which are more relevant to
patients. However, the drawback of this approach is that
these outcome measure are often more difficult to blind.
We have described in this paper the strategies used to
reduce this risk of bias, leading to patient-relevant
outcomes with minimal risks of bias. In the TRIGGER
trial, the outcome definition for further bleeding was
modified to exclude the subjective aspects of the definition
(for example, clinician assessment of whether patient
symptoms were severe enough to indicate bleeding),
leaving only the most objective aspects (the presence
versus absence of active bleeding visualised in the upper
gastrointestinal tract). In the TAPPS trial, the outcome
was modified so that the unblinded clinician could only
refer the patient for a further procedure when clearly indi-
cated based on the patient’s chest x-ray; otherwise, they
needed to reach consensus with a blinded clinician.
Although these strategies should reduce the risk of
bias, they are not without limitations. The requirement
in TAPPS to use a second (blinded) clinician to assess
the patient added extra complexity to the trial, as it
required more effort to ensure that clinicians who were
not directly involved with the patient were kept blinded,
that these clinicians were available to assess the patient
when needed, and that this assessment procedure was
being followed as specified. The requirement in TRIG-
GER for all episodes of further bleeding to be confirmed
via a procedure (endoscopy, surgery, or radiology) meantthat a very small number of bleeding episodes may have
been missed in patients who were too unwell to receive
a procedure. However, in both cases the benefits of the
outcome modification far outweigh the limitations.
Developments in multimedia technology have made
blinded assessment for outcomes based on visual inspec-
tion (such as further bleeding in TRIGGER) more feasible,
as there are often affordable ways of taking high-quality
pictures, videos, or other digital recordings, which can be
given to an independent adjudicator for assessment. This
type of technology has been used in other gastrointestinal
trials, for example in the assessment of degree of colonic
inflammation in trials of ulcerative colitis [22]. It was
felt this type of assessment would not be feasible for
TRIGGER due to the difficulties in implementing a new
technology across entire hospitals for use in emergency
medical settings, particularly in terms of training staff
to comply with regulatory and good clinical practice
guidelines. However, as trialists become more familiar
with the use of multimedia technology in their trials,
implementation should become easier, allowing for more
objective outcome assessments in certain situations.
Conclusions
Outcome assessment should be blinded when possible.
In scenarios where this is not feasible, it may be beneficial
to modify the outcome definition or method of assessment
to minimise the subjective elements, to ensure that results
are as robust as possible to the lack of blinding.
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